2024
Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S
Shah S, Chou B, Patel M, Watane A, Shah L, Yannuzzi N, Sridhar J. Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S. Current Opinion In Ophthalmology 2024, 35: 369-375. PMID: 39115058, DOI: 10.1097/icu.0000000000001076.Peer-Reviewed Original Research
2022
Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration
Sood S, Mandell J, Watane A, Friedman S, Parikh R. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology 2022, 140: 716-723. PMID: 35708679, PMCID: PMC9204613, DOI: 10.1001/jamaophthalmol.2022.1819.Peer-Reviewed Original ResearchConceptsRanibizumab port delivery systemPort Delivery SystemBevacizumab injectionIntravitreal ranibizumabNeovascular AMDBimonthly injectionsIntravitreal anti-vascular endothelial growth factor injectionsAnti-vascular endothelial growth factor injectionsIntravitreal anti-VEGF injectionsEndothelial growth factor injectionsTotal direct medical costsAnti-VEGF injectionsIntravitreal bevacizumab injectionGrowth factor injectionsDirect medical costsAge-related macularMedicare reimbursement ratesAflibercept injectionsNeovascular AgeFactor injectionsIntravitreal injectionMacular degenerationMAIN OUTCOMERanibizumabMedical costs